Stryker (SYK) Stock Forecast & Price Target

$393.85 +2.97 (+0.76%)

As of 03:22 PM Eastern

Stryker - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 19 Analyst Ratings

Sell
0

Hold
4

Buy
15

Based on 19 Wall Street analysts who have issued ratings for Stryker in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 19 analysts, 4 have given a hold rating, and 15 have given a buy rating for SYK.

Consensus Price Target

$430.10
9.20% Upside

According to the 19 analysts' twelve-month price targets for Stryker, the average price target is $430.10. The highest price target for SYK is $456.00, while the lowest price target for SYK is $370.00. The average price target represents a forecasted upside of 9.20% from the current price of $393.85.

Get the Latest News and Ratings for SYK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stryker and its competitors.

SYK Analyst Ratings Over Time

Type	Current Forecast 8/26/24 to 8/26/25	1 Month Ago 7/27/24 to 7/27/25	3 Months Ago 5/28/24 to 5/28/25	1 Year Ago 8/27/23 to 8/26/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)	15 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$430.10	$428.55	$427.30	$373.11
Forecasted Upside	9.20% Upside	6.25% Upside	12.37% Upside	5.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

SYK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SYK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Stryker Stock vs. The Competition

Type	Stryker	Medical Companies	S&P 500
Consensus Rating Score	2.79	2.79	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	9.73% Upside	14,032.30% Upside	10.61% Upside
News Sentiment Rating	Very Positive News See Recent SYK News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/4/2025	Truist Financial 3 of 5 stars	Richard Newitter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Hold ➝ Hold	$410.00 ➝ $415.00	+8.79%
8/1/2025	Wells Fargo & Company 3 of 5 stars	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$435.00 ➝ $445.00	+17.27%
8/1/2025	Needham & Company LLC 2 of 5 stars	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$442.00 ➝ $448.00	+13.89%
7/14/2025	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
7/8/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$390.00 ➝ $415.00	+5.80%
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$443.00 ➝ $455.00	+20.09%
5/5/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$450.00	+17.24%
5/5/2025	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Turkaly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/2/2025	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jason Wittes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$405.00 ➝ $456.00	+20.75%
3/4/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target		$422.00	+12.41%
Get the Latest News and Ratings for SYK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Stryker and its competitors with MarketBeat's FREE daily newsletter.
2/10/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$418.00 ➝ $443.00	+13.18%
2/3/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$450.00	+17.62%
1/29/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$425.00 ➝ $435.00	+11.57%
1/29/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$420.00 ➝ $445.00	+12.68%
1/29/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$400.00 ➝ $440.00	+11.41%
1/29/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kyle Rose Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$420.00 ➝ $435.00	+10.15%
12/2/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$370.00 ➝ $445.00	+13.48%
10/30/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$380.00 ➝ $420.00	+17.04%
10/30/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$366.00 ➝ $370.00	+2.61%
10/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$378.00 ➝ $405.00	+12.73%
9/10/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$405.00	+11.64%
4/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$365.00 ➝ $400.00	+15.82%
9/5/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$310.00 ➝ $315.00	+10.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:22 PM ET.

Should I Buy Stryker Stock? SYK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 23, 2025. Please send any questions or comments about these Stryker pros and cons to contact@marketbeat.com.

Stryker
Bull Case

Here are some ways that investors could benefit from investing in Stryker Co.:

The current stock price is around $445, reflecting a positive outlook from analysts who have recently upgraded their target prices.
Stryker Co. has a solid annualized dividend of $3.36, providing a dividend yield of 0.9%, which can be attractive for income-focused investors.
The company has a relatively low dividend payout ratio of 44.50%, indicating that it retains a significant portion of its earnings for reinvestment, which can support future growth.
Fifteen analysts have rated the stock as a Buy, suggesting strong confidence in the company's future performance.
Recent earnings guidance for FY 2025 is set at 13.400-13.600 EPS, indicating expected growth in profitability.

Stryker
Bear Case

Investors should be bearish about investing in Stryker Co. for these reasons:

Despite the positive outlook, the stock has seen fluctuations, and recent insider selling by a director could raise concerns about the company's short-term prospects.
The dividend yield of 0.9% is relatively low compared to other investment opportunities, which may not attract all income-focused investors.
Analysts have mixed ratings, with some holding a "market perform" rating, indicating that not all experts are fully confident in the stock's potential for significant growth.
Market volatility and economic uncertainties could impact Stryker Co.'s performance, especially in the medical technology sector.
With a significant portion of shares owned by corporate insiders, any major selling activity could negatively affect stock prices.

SYK Forecast - Frequently Asked Questions

: According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for Stryker is $430.10, with a high forecast of $456.00 and a low forecast of $370.00.
: 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SYK shares.
: According to analysts, Stryker's stock has a predicted upside of 9.20% based on their 12-month stock forecasts.
: Stryker has been rated by research analysts at BTIG Research, Evercore ISI, Needham & Company LLC, Truist Financial, and Wells Fargo & Company in the past 90 days.
: Analysts like Stryker more than other "medical" companies. The consensus rating score for Stryker is 2.79 while the average consensus rating score for "medical" companies is 2.79. Learn more on how SYK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:SYK) was last updated on 8/26/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stryker (SYK) Stock Forecast & Price Target